Literature DB >> 29096240

Features of continuous glycemic profile and glycemic variability in patients with obstructive sleep apnea syndrome.

Chao-Sheng Peng1, Yue-An Cao1, Yu-Hong Tian1, Wen-Luo Zhang1, Jing Xia1, Lu Yang2.   

Abstract

AIMS: To investigate glycemic variability (GV) in Obstructive Sleep Apnea Syndrome (OSAS) patients by monitoring continuous blood glucose profile.
METHODS: OSAS group (n=86) and normal control group (n=40) were included. Continuous blood glucose was monitored. The relationship of GV, insulin resistance index (IRI) and the respiratory disturbance index (AHI) were analyzed.
RESULTS: The daily average blood glucose level was significantly higher in the OSAS patients than in the control group (6.31±0.61vs. 4.94±0.78; P<0.01). The postprandial glycemic peaks in the OSAS patients were significantly higher and prolonged. The indicators of GV were all significantly higher in the OSAS patients, including blood glucose fluctuation coefficient (BGFC, 1.93±0.71vs. 1.21±0.38, P<0.05), mean amplitude of glycemic excursions (MAGE, 4.18±0.65vs. 2.18±0.48; P<0.05) and night mean amplitude of glycemic excursions (NMAGE, 2.00±0.53vs. 1.11±0.43; P<0.05). Pearson correlation analysis showed that among the OSAS patients, the severity of OSAS (AHI) was positively correlated with the IRI (r=0.310); and the GV indicators (MAGE and NMAGE) were positively correlated with IRI and AHI (r=0.318 and 0.349, respectively) (P<0.01 or 0.001).
CONCLUSIONS: Continuous glycemic spectrum and GV provide comprehensive glycemic profiles and may reveal important aspects of glucose metabolism abnormality beyond regular examinations, and are therefore of particular significance for glycemic management in OSAS patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Continuous blood glucose profile; Glycemic variability; Insulin resistance; MAGE, NMAGE; Obstructive sleep apnea syndrome (OSAS)

Mesh:

Substances:

Year:  2017        PMID: 29096240     DOI: 10.1016/j.diabres.2017.08.010

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

Review 1.  A Review of the Associations Between Obstructive Sleep Apnea and Gestational Diabetes Mellitus and Possible Mechanisms of Disease.

Authors:  Xingyi Tong; Linzhu Yang; Chengyan Jiang; Zhiying Weng; Anju Zu; Yunjiao Hou; Yan Fang; Weimin Yang; Shibo Sun
Journal:  Reprod Sci       Date:  2022-03-07       Impact factor: 3.060

2.  Blood glucose dynamics during sleep in patients with obstructive sleep apnea and normal glucose tolerance: effects of CPAP therapy.

Authors:  Kimimasa Saito; Yosuke Okada; Keiichi Torimoto; Yoko Takamatsu; Yoshiya Tanaka
Journal:  Sleep Breath       Date:  2021-08-11       Impact factor: 2.655

3.  Sleep quality and glycaemic variability in a real-life setting in adults with type 1 diabetes.

Authors:  Rachel Brandt; Minsun Park; Kristen Wroblewski; Lauretta Quinn; Esra Tasali; Ali Cinar
Journal:  Diabetologia       Date:  2021-06-17       Impact factor: 10.460

4.  A study of glycemic variability in patients with type 2 diabetes mellitus with obstructive sleep apnea syndrome using a continuous glucose monitoring system.

Authors:  Suhas S Khaire; Jugal V Gada; Ketaki V Utpat; Nikita Shah; Premlata K Varthakavi; Nikhil M Bhagwat
Journal:  Clin Diabetes Endocrinol       Date:  2020-06-05

5.  Dynamic changes in nocturnal blood glucose levels are associated with sleep-related features in patients with obstructive sleep apnea.

Authors:  Jung-Ick Byun; Kwang Su Cha; Ji Eun Jun; Tae-Joon Kim; Ki-Young Jung; In-Kyung Jeong; Won Chul Shin
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

6.  Postprandial glucose and HbA1c are associated with severity of obstructive sleep apnoea in non-diabetic obese subjects.

Authors:  A Cignarelli; A Ciavarella; M Barbaro; S Kounaki; A Di Trani; V A Falcone; V N Quaranta; A Natalicchio; L Laviola; O Resta; F Giorgino; S Perrini
Journal:  J Endocrinol Invest       Date:  2021-06-26       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.